Jia Shidong, Zocco Davide, Samuels Michael L, Chou Michael F, Chammas Roger, Skog Johan, Zarovni Natasa, Momen-Heravi Fatemeh, Kuo Winston Patrick
Oncology Biomarker Development, Genentech Inc., South San Francisco, CA 94080, USA.
Expert Rev Mol Diagn. 2014 Apr;14(3):307-21. doi: 10.1586/14737159.2014.893828. Epub 2014 Feb 27.
Extracellular vesicles (EVs), including exosomes and microvesicles, have been shown to carry a variety of biomacromolecules including mRNA, microRNA and other non-coding RNAs. Within the past 5 years, EVs have emerged as a promising minimally invasive novel source of material for molecular diagnostics. Although EVs can be easily identified and collected from biological fluids, further research and proper validation is needed in order for them to be useful in the clinical setting. In addition, innovative and more efficient means of nucleic acid profiling are needed to facilitate investigations into the cellular and molecular mechanisms of EV function and to establish their potential as useful clinical biomarkers and therapeutic tools. In this article, we provide an overview of recent technological improvements in both upstream EV isolation and downstream analytical technologies, including digital PCR and next generation sequencing, highlighting future prospects for EV-based molecular diagnostics.
细胞外囊泡(EVs),包括外泌体和微囊泡,已被证明可携带多种生物大分子,包括信使核糖核酸(mRNA)、微小核糖核酸(microRNA)和其他非编码核糖核酸。在过去5年里,细胞外囊泡已成为一种有前景的用于分子诊断的微创新型材料来源。尽管细胞外囊泡可轻易从生物体液中识别和收集,但要使其在临床环境中发挥作用,仍需进一步研究和适当验证。此外,需要创新且更高效的核酸分析方法,以促进对细胞外囊泡功能的细胞和分子机制的研究,并确定其作为有用的临床生物标志物和治疗工具的潜力。在本文中,我们概述了细胞外囊泡上游分离和下游分析技术(包括数字聚合酶链反应和下一代测序)的近期技术改进,突出了基于细胞外囊泡的分子诊断的未来前景。